Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
E. David Crawford1, David Albala2, Marc B. Garnick3, Andrew W. Hahn4, Paul Maroni5, Rana R. McKay6, Martin Miner7, Peter Orio III8, Kshitij Pandit1, Scott Sellinger9, Evan Y. Yu10, Robert H. Eckel11
Canadian Journal of Urology, Vol.31, No.2, pp. 11820-11825, 2024
Abstract Introduction: Risk of cardiovascular disease is higher
among men with prostate cancer than men without,
and prostate cancer treatments (especially those that
are hormonally based) are associated with increased
cardiovascular risk.
Materials and methods: An 11-member panel of
urologic, medical, and radiation oncologists (along
with a men’s health specialist and an endocrinologist/
preventive cardiologist) met to discuss current practices
and challenges in the management of cardiovascular
risk in prostate cancer patients who are taking androgen
deprivation therapies (ADT) including LHRH analogues,
alone and in combination with androgen-targeted
therapies (ATTs).
Results: The panel developed an assessment algorithm
to categorize… More >